Oncology

News

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting

News

Novartis adds clinical-stage protein degrader from Arvinas

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in

News

Essential adds neuroblastoma drug with Renaissance buy

Essential Pharma has bought fellow UK drugmaker Renaissance Pharma, adding its first development-stage drug candidate, a therapy for hard-to-treat rare cancer neuroblastom

News

UK survey finds deep ethnic divisions in cancer diagnosis

A UK report has found that people from minority ethnic backgrounds face an average delay of a year between first noticing symptoms and gaining a diagnosis, which is more t

News

Study points to weaknesses in FDA accelerated approval path

Less than half of the cancer therapies that were granted accelerated approval by the FDA between 2013 and 2017 showed a clinical benefit in a confirmatory trial within the

News

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

The FDA has approved the use of AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu for all HER2-positive solid tumours, in a first for both HER2 inhibitors a

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

Novartis adds clinical-stage protein degrader from Arvinas

Essential adds neuroblastoma drug with Renaissance buy

UK survey finds deep ethnic divisions in cancer diagnosis

Study points to weaknesses in FDA accelerated approval path

Enhertu gets FDA nod for tumour-agnostic HER2 cancers

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

Oncology

Editor's Picks